NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock Q3 2026 Earnings Results & Report $22.94 +0.86 (+3.89%) As of 04:00 PM Eastern Damora Therapeutics, Inc. Common Stock beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.40 versus the -$0.52 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call7:00 AM ET Damora Therapeutics, Inc. Common Stock EPS ResultsActual EPS-$0.40Consensus EPS -$0.52Beat/MissBeat by +$0.12One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersDamora Therapeutics, Inc. Common Stock Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Damora Therapeutics, Inc. Common Stock Q3 2026 Earnings FAQ Did Damora Therapeutics, Inc. Common Stock beat earnings estimates for Q3 2026? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) reported earnings of -$0.40 per share for Q3 2026, beating the consensus estimate of -$0.52. The report was announced on Wednesday, November 4, 2026. Damora Therapeutics, Inc. Common Stock Earnings HeadlinesDamora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights3 hours ago | globenewswire.comDamora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual MeetingNovember 4 at 9:00 AM | globenewswire.comElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.November 4 at 1:00 AM | Brownstone Research (Ad)Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Lowered by Wall Street ZenOctober 31, 2026 | americanbankingnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comDamora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC FilingSeptember 29, 2026 | marketscreener.comMSee More Damora Therapeutics, Inc. Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Damora Therapeutics, Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Damora Therapeutics, Inc. Common Stock and other key companies, straight to your email. Email Address About Damora Therapeutics, Inc. Common StockGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.View Damora Therapeutics, Inc. Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
